en · de · es · fr · pt
cardarine-notes.peptides6579.com › Faq › Identity And Pharmacological Classification — Worked Examples

Identity And Pharmacological Classification — Worked Examples

By Editorial Desk · published 2026-03-29 · last reviewed 2026-05-01 · Faq

Prohibited substance comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2026-05-01. Numbers and descriptions here follow the published literature rather than marketing material.

Identity and Pharmacological Classification

Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.

Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.

PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.

Cardarine as Investigational PPARδ Agonist

The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.

Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.

Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.

Cardarine at a glance

PropertyValueNotes
Chemical classPPARδ agonistNot an anabolic steroid.
Common synonymsGW501516, GW-1516Cardarine is an informal name.
AppearanceWhite to off-white powderTypical for research-grade solid.
Solubility classPoorly soluble in water; soluble in some organic solventsSuch as DMSO or ethanol in laboratory settings.
Typical storage temperatureCool, dry, protected from lightSpecific conditions vary by supplier and form.

Regulation and Analytical Detection

Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.

Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.

Related pages on this site

Regulation and Detection

Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.

Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.

Background and Regulatory History

Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.

Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.

GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.

Notes from published material

=== April === 3 April – Ted Hipkiss, cricketer (Northern Districts) (born 1947). 5 April Raymond Hawthorne, actor (Mortimer's Patch, Bread and Roses, Shortland Street) and theatre director (Mercury Theatre, National Opera of New Zealand) (born 1936). Di McCarthy, behavioural neuroscientist (University of Auckland), chief executive of the Royal Society of New Zealand Te Apārangi (2007–2014). 6 April Sue Berry, physiotherapist and businesswoman, co-founder of Whitestone Cheese (1987) (born 1944). Avis Fletcher, Olympic hurdler and sprinter (1964), British Empire and Commonwealth Games double bronze medallist (1962) (born 1938). 9 April Nancy Carr, home economist (University of Otago) (born 1936). John Mayhew, sports physician (All Blacks, North Harbour, New Zealand Warriors) (born 1954). 11 April – Robyn Kahukiwa, artist, children's writer and illustrator, Te Tohu mō Te Arikinui Dame Te Atairangikaahu (2020) (born 1938). 13 April John Bradshaw, geologist (University of Canterbury), Fellow of the Royal Society of New Zealand (since 1999) (born 1939). David Kernohan, architect and academic (Victoria University of Wellington) (born 1947). 14 April – Peter Matheson, theologian (University of Otago) (born 1938). 16 April – Roger McLachlan, rock bassist (Little River Band) (born 1954). 18 April – Bill Woods, local politician and community leader, Mayor of Selwyn (1992–1995) (born 1942). 19 April – Peter Hilt, politician, MP for Glenfield (1990–1996) (born 1942).

Dualism A philosophical position asserting that the mind and body are fundamentally distinct entities. In neuroscience, it contrasts with monistic and physicalist views of consciousness. Dynein A motor protein that moves along microtubules in the cytoskeleton, transporting cellular cargo toward the center of the cell. In neurons, dynein is important for retrograde axonal transport. Dysarthria A motor speech disorder resulting from impaired control of the muscles used in speech, often due to neurological damage to the brainstem or cerebellum. Dyskinesia Involuntary, erratic, or repetitive movements, often associated with long-term use of dopaminergic drugs in Parkinson’s disease. Dyslexia A neurodevelopmental disorder characterized by difficulty with accurate and/or fluent word recognition, often linked to deficits in phonological processing and left hemisphere brain function. Dyspraxia A developmental coordination disorder involving difficulty with motor planning and execution, affecting balance, fine motor tasks, and speech.

== Cited literature == Bilstein, Roger E. (1996). Stages to Saturn: A Technological History of the Apollo/Saturn Launch Vehicles. Washington: Scientific and Technical Information Branch, National Aeronautics and Space Administration. ISBN 0-16-048909-1. Burgess, Colin; Hall, Rex (2009). The First Soviet Cosmonaut Team. Chichester, UK: Praxis Publishing. ISBN 978-0-387-84824-2. LCCN 2008935694. Burgess, Colin; Kate Doolan; Bert Vis (2003). Fallen Astronauts: Heroes Who Died Reaching for the Moon. Lincoln: University of Nebraska Press. ISBN 0-8032-6212-4. Brzezinski, Matthew (2007). Red Moon Rising: Sputnik and the Hidden Rivalries that Ingnited the Space Race. New York: Times Books, Henry Holt and Company. ISBN 978-0-8050-8147-3. Burrows, William E. (1998). This New Ocean: The Story of the First Space Age. New York: Random House. ISBN 978-0-679-44521-0. Cadbury, Deborah (2006). Space Race: The Epic Battle Between America and the Soviet Union for Dominance of Space. New York: Harper Collins Publishers. ISBN 978-0-06-084553-7. Chaikin, Andrew (1994). A Man on the Moon: The Triumphant Story of the Apollo Space Program. New York: Penguin Books. ISBN 0-14-027201-1. Chertok, Boris (2005). Rockets and People Volumes 1-4. National Aeronautics and Space Administration. Retrieved May 29, 2022. Cornwell, John (2003). Hitler's Scientists: Science, War, and the Devil's Pact. New York: Viking Press. ISBN 0-670-03075-9. Dallek, Robert (2003). An Unfinished Life: John F. Kennedy, 1917–1963. Boston: Little, Brown and Company. ISBN 0-316-17238-3. Leonard, David (2019). Moon Rush.

Are, or think they may be, pregnant Have abnormal vaginal bleeding that has not been explained (controversial) Have untreated cervical or uterine cancer Have, or may have, breast cancer Have abnormalities of the cervix or uterus (controversial) Have had pelvic inflammatory disease within the past three months Have had an STI such as chlamydia or gonorrhea within the past three months Have liver disease or tumor Have an allergy to levonorgestrel or any of the inactive ingredients included in the device Insertion of an IUD is acceptable after a dilation and evacuation (D&E) abortion (second-trimester abortion), but may be associated with a higher expulsion rate. To reduce the risk of infection, insertion of an IUD is not recommended for women that have had a medical abortion but have not yet had an ultrasound to confirm that the abortion was complete, or that have not yet had their first menstruation following the medical abortion. A full list of contraindications can be found in the WHO Medical Eligibility Criteria for Contraceptive Use and the CDC United States Medical Eligibility Criteria for Contraceptive Use.

Sources: en.wikipedia.org

Further detail

Filtering helps stabilise the flavour of beer, holding it at a point acceptable to the brewer, and preventing further development from the yeast, which under poor conditions can release negative components and flavours. Filtering also removes haze, producing a clear beer with a "polished shine and brilliance". Clear beer became commercially desirable with the increasing use of glass drinking vessels and the development of pale lagers. During lagering, suspended material settles out, allowing the beer to "drop bright" and develop a naturally clear appearance. There are several forms of filters; they may be in the form of sheets or "candles", or they may be a fine powder such as diatomaceous earth (also called kieselguhr), which is added to the beer to form a filtration bed which allows liquid to pass, but holds onto suspended particles such as yeast. Filters range from rough filters that remove much of the yeast and any solids (e.g., hops, grain particles) left in the beer, to filters tight enough to strain colour and body from the beer. Filtration ratings are divided into rough, fine, and sterile. Rough filtration leaves some cloudiness and some character in the beer, while Fine filtration removes almost all cloudiness and microorganisms. Polysaccharides, proteins, yeast, bacteria and the brewing process may affect filtration.

==== Apixaban binding to factor Xa ==== Apixaban shows a similar binding mode as rivaroxaban and forms a tight inhibitor-enzyme complex when connected to FXa. The p-methoxy group of apixaban connects to S1 pocket of FXa but does not appear to have any interaction with any residues in this region of FXa. The pyrazole N-2 nitrogen atom of apixaban interacts with Gln-192 and the carbonyl oxygen interacts with Gly-216. The phenyl lactam group of apixaban is positioned between Tyr-99 and Phe-174 and due to its orientation, it is able to interact with Trp-215 of the S4 pocket. The carbonyl oxygen group of the lactam moiety interacts with a water molecule and does not seem to interact with any residues in the S4 pocket.

The result of this process is loss of CO2 and emission of a photon of blue light at ~460 nm. This reaction has an optimal pH of 9, optimal salt concentration of 0.05-0.1 M, and optimal temperature of ~40 C (making it an unusually heat resistant luciferase), although because O.gracilirostris are deep sea animals living in below 20 C temperatures, luciferase is normally expressed and folded at low temperatures.

I have not done anything wrong." Law enforcement made no allegations of wrongdoing against Pritzker, and he has said: "over decades of my life, I have been doing public service, and the opportunity to continue to do public service as treasurer of the state was something that had been brought up, and so there was a conversation about that." Pritzker later apologized for certain comments he made in the recorded conversation. After the recording was released, White continued to support Pritzker in his 2018 gubernatorial campaign and accepted his apology, saying he knew "where his heart is" and "I consider him a very good friend".

Le Cake-Walk infernal, sold in the United States as The Cake Walk Infernal and in Britain as The Infernal Cake Walk, is a 1903 French silent trick film by Georges Méliès. It was sold by Méliès's Star Film Company and is numbered 453–457 in its catalogues. The film features the cakewalk, which was booming in popularity in 1903. Méliès appears in the film as Pluto/Satan and as the grotesque dancing demon. This rhythm-dependent film was probably filmed to piano accompaniment in the studio. Special effects in the film were worked with trapdoors, stage machinery, pyrotechnics, substitution splices, and multiple exposures. The Infernal Cake Walk features several examples of elements reused from, or later reused in, other films also made by Méliès. The demon masks in the film were originally made for Méliès's A Trip to the Moon (1902), where they are worn by the Selenites (Moon dwellers); similarly, the effect of dancing limbs had previously been used in Dislocation Extraordinary (1901). Conversely, Méliès reused The Infernal Cakewalk's grotto set in his later film The Damnation of Faust (1903), and recycled the will-o'-the-wisp effect in The Infernal Cauldron (1903).

Sources: en.wikipedia.org

Supporting material

== History == The prostate was first formally identified by Venetian anatomist Niccolò Massa in Anatomiae libri introductorius (Introduction to Anatomy) in 1536 and illustrated by Flemish anatomist Andreas Vesalius in Tabulae anatomicae sex (six anatomical tables) in 1538. Massa described it as a "glandular flesh upon which rests the neck of the bladder," and Vesalius as a "glandular body". The first time a word similar to prostate was used to describe the gland is credited to André du Laurens in 1600, who described it as a term already in use by anatomists at the time. The term was however used at least as early as 1549 by French surgeon Ambroise Pare. At the time, Du Laurens was describing what was considered to be a pair of organs (not the single two-lobed organ), and the Latin term prostatae that was used, meaning "one who stands before," "leader" or "guardian," was a mistranslation of the term for the Ancient Greek word used to describe the seminal vesicles, parastatai adenoeides, meaning "glandular assistants". Some have argued that surgeons in Ancient Greece and Rome must have at least seen the prostate as an anatomical entity, but other authors state that because prostatic anatomy varies greatly among species, and almost all anatomical dissection before the Renaissance was performed on animals, it is likely that the prostate was not recognized as a distinct organ. The term prostatae was taken rather than the grammatically correct prostator (singular) and prostatores (plural) because the gender of the Ancient Greek term was taken as female, when it was in fact male.

Bodybuilding is the practice of progressive resistance exercise to build, control, and develop one's muscles via hypertrophy. An individual who engages in this activity is referred to as a bodybuilder. It is primarily undertaken for aesthetic purposes over functional ones, distinguishing it from similar activities such as powerlifting and calisthenics. In competitive bodybuilding, competitors appear onstage in line-ups and perform specified poses (and later individual posing routines) for a panel of judges who rank them based on conditioning, muscularity, posing, size, stage presentation, and symmetry. Bodybuilders prepare for competitions by exercising and eliminating non-essential body fat. This is enhanced at the final stage by a combination of carbohydrate loading and dehydration to achieve maximum muscle definition and vascularity. Most bodybuilders also tan and shave their bodies prior to competition.

In enzymology, an aromatic 2-oxoacid reductase (EC 1.1.1.110, previously indolelactate dehydrogenase) is an enzyme that catalyzes the reversible oxidation and reduction of aryllactate compounds to arylpyruvate compounds using the redox cofactor nicotinamide adenine dinucleotide or the similar nicotinamide adenine dinucleotide phosphate. For example, the enzyme may oxidize (R)-3-(4-hydroxyphenyl)lactate to 3-(4-hydroxyphenyl)pyruvic acid.

Moreover, both the refractive index and the optical absorption are found to be dispersionless over a broad wavelength range from visible to near infrared. Finally, GO film offers flexible patterning capability by using the maskless DLW method, which reduces the manufacturing complexity and requirements. As a result, a novel ultrathin planar lens on a GO thin film has been realized recently using the DLW method. The distinct advantage of the GO flat lens is that phase modulation and amplitude modulation can be achieved simultaneously, which are attributed to the giant refractive index modulation and the variable linear optical absorption of GO during its reduction process, respectively. Due to the enhanced wavefront shaping capability, the lens thickness is pushed down to subwavelength scale (~200 nm), which is thinner than all current dielectric lenses (~ μm scale). The focusing intensities and the focal length can be controlled effectively by varying the laser powers and the lens sizes, respectively. By using an oil immersion high numerical aperture (NA) objective during DLW process, 300 nm fabrication feature size on GO film has been realized, and therefore the minimum lens size has been shrunk down to 4.6 μm in diameter, which is the smallest planar micro lens and can only be realized with metasurface by FIB. Thereafter, the focal length can be reduced to as small as 0.8 μm, which would potentially increase the numerical aperture (NA) and the focusing resolution.

19 October – The SNP appoints Carol Beattie, a former chief executive of Stirling Council, as interim chief executive following the resignation of Murray Foote. 20 October – The UK government announces plans to appoint a minister to oversee the building of HS2, as well as confirming it will not reinstate the route's Birmingham to Manchester leg. The Sunday Times reports that Rushanara Ali has given up responsibility for managing building safety after survivors of the Grenfell tower fire called for her to stand down following an article that highlighted her attendance at the Franco-British Colloque, a conference that brings together senior politicians, civil servants and business leaders. 21 October – A Freedom of Information request reveals that Suella Braverman sent government documents to her private email account 127 times while she was Attorney General, potentially breaching the ministerial code. 22 October – The Welsh Government pays a £19m tax bill for the environment agency, Natural Resources Wales, following a HM Revenue and Customs investigation into how the agency hired specialist contractors. The UK signs what it has described as a "landmark defence agreement" with Germany. 23 October – Charles III and Camilla arrive in Samoa for a state visit, where the King will preside over the 2024 Commonwealth Heads of Government Meeting. The Senedd votes 26–19 to defeat a motion calling for a new law to allow assisted dying in England and Wales.

Sources: en.wikipedia.org

Frequently asked questions

What is cardarine also known as?

Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.

Is cardarine a steroid?

No, cardarine is not a steroid. It is classified as a PPARδ agonist. Its structure and receptor target differ from anabolic steroids.

Has cardarine been approved for human use?

No regulatory agency has approved cardarine as a medicine. It was investigated in early research but development was discontinued. It is not available as a prescription drug.

What is cardarine?

Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.

Network